The Future of EDETEK's R&D Cloud

In this Pharmaceutical Executive video interview, Dr. Shakthi Kumar, Chief Strategy and Business Officer, EDETEK, Inc. further explores the company's launch of R&D Cloud, emphasizing the platform's open API access, extensive library of pre-built connectors for various data sources, and real-time data and workflow capabilities.

He highlights key differentiators including the breadth and depth of integrated capabilities (covering the entire clinical trial lifecycle), robust workflow and event management, multi-SSO integration, and a state-of-the-art cloud architecture.

Future development plans include incorporating AI, expanding connectors, and specializing in additional therapeutic areas. Ultimately, the R&D Cloud aims to provide cost reduction, improved business outcomes (faster trials, real-time insights), and enhanced data quality and compliance for clients.

A transcription of the conversation is available below.

Are there future development plans for the R&D Cloud ecosystem?

We have very ambitious development plans for the R&D Cloud ecosystem. We continue to invest in a number of areas, and you know, I can probably highlight a few. We are incorporating advanced, of course, artificial intelligence capabilities within the RNA cloud, specifically agentic AI and machine learning technologies to drive better insights and decision making for our clients. So that's something that's ongoing.

The second one is we are expanding the list of upstream and downstream connectors. This is to make it easy to integrate our R&D Cloud, with other third-party software, and we expect to continue to partner with others. For us partnership is a key tenet of what we want to do, so we will continue to do that. And we will double down and specialize in other therapeutic areas as well. I talked about on cop loss, but next in the line, we're working on CNS and that immunology. So, I think we do believe that that provides, you know, significant benefits to the industry, you know, getting much needed therapies faster to patients. And so those are some of the areas we're looking at right now.

How does the R&D Cloud translate into tangible benefits for EDETEK's clients?

Tangibility comes in three different ways. The first one is the best metric for tangibility is cost reduction, so they can incrementally layer our R&D Cloud offering in. To existing operational environments where there are gaps to really build an ecosystem. So, there is no need to replace an expensive, lift and shift of their existing environments, as well as costly integrations, because our on the cloud already comes prebuilt with over 80 different integrations with major software, so cost reduction is one.

The second one is in terms of business outcomes. We do believe it has significantly helped our clients to improve the speed and efficiency of clinical trial execution. Miranda, just to give you an overview today, our platform is used by over 100 Life Sciences organizations. We have our conform platform. And eClinical platforms have managed over 3 billion data points, including many, many mega trials. In terms of business outcomes, we're very confident in driving faster study start up, as well as real time data insights and accelerated regulatory submissions, right? So that's kind of driving business outcomes. Is a key benefit to our clients.

The third one is improved data quality and compliance. The platform, we have robust, you know, validation rules, we have alerts as well as a whole library of checks that we perform on the data that's ingested into the R&D Cloud, which means that the data quality improves, as well as compliance to various regulatory standards, right? Those are kind of three tangible benefits, as I mentioned earlier, we are really excited for our clients that the dream of build your own R&D Cloud is actually becoming a reality, and we here to support it.